Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 4;13:1790. doi: 10.1038/s41467-022-29286-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — a, b The anti-tumor activity of ALPN-202 was significantly blocked by combining with (a) anti-hPD-L1 or (b) anti-mCD28 blocking antibodies (n = 12 mice/group). Mean tumor volumes ± SEM are shown. Tumors were collected from mice 48 h after the second dose, dissociated, and analyzed by flow cytometry. ALPN-202 treatment significantly increased the percentage of infiltrating total CD3⁺ T cells (c), CD8⁺ T cells (d), and granzyme B⁺ CD8⁺ T cells (e) relative to Fc Control treated animals. In each case, this influx in T cells was reduced when ALPN-202 was combined with anti-hPD-L1 or anti-mCD28 antibodies. Statistical significance was determined by repeated-measures two-way ANOVA for treatment effects (a, b) or one-way ANOVA with Dunnett’s multiple comparisons test (c–e). Bar height indicates mean value ± SEM and symbols represent individual tumor samples (n = 5 tumors per treatment group) (c–e). Source data are provided as a Source Data file.